Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
Phase 1
Completed
NCT06422767
| Condition | Hepatitis B |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | GlaxoSmithKline |
|---|
| Status | Completed |
|---|
| Enrollment | 46 participants |
|---|
| Interventions | Bepirovirsen |
|---|
| Start date | Jul 18, 2024 |
|---|
| Completion date | Apr 28, 2025 |
|---|
| Results posted | Jul 10, 2026 |
|---|
Summary
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
Placebo-corrected Change From Baseline (CFB) in QT Interval Corrected by Fridericia's Formula (QTcF) Following Administration of Bepirovirsen Supratherapeutic Single Dose
Baseline (Pre-dose on Day 1) and Day 4 · Milliseconds
| Bepirovirsen: Four-Dose SC Injection | 2.360 Milliseconds |
|---|
| Bepirovirsen: Three-Dose SC Injection | 2.024 Milliseconds |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.